• About Us
    • Our Company
    • Management & Board
    • Who We Help
  • Our Approach
    • Toll-Like Receptor Activation
    • Publications & Presentations
  • Areas of Focus
    • Immuno-Oncology
    • Pipeline & Programs
  • Investor Relations
  • Join Us
×

Design of a randomized, double-blind, placebo-controlled Phase 2 clinical trial of IMO-8400, a Toll-like receptor antagonist, in patients with dermatomyositis

© 2022 Idera. All rights reserved.

  • Contact Us
  • Terms of Use
  • Privacy Policy